From 2016 to 2021 the European Treatment and Outcome Study for CML (EUTOS) explored the use of secondary, lyophilized cell-based BCR::ABL1 reference panels traceable to the World Health Organization primary reference material to standardize and validate local laboratory tests. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.